- Home
- MOLN vs CIA Comparison
MOLN vs CIA Comparison
Compare MOLN & CIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- CIA
- Stock Information
- Founded
- MOLN 2004
- CIA 1969
- Country
- MOLN Switzerland
- CIA United States
- Employees
- MOLN N/A
- CIA N/A
- Industry
- MOLN
- CIA Life Insurance
- Sector
- MOLN
- CIA Finance
- Exchange
- MOLN Nasdaq
- CIA Nasdaq
- Market Cap
- MOLN 192.4M
- CIA 230.6M
- IPO Year
- MOLN 2021
- CIA N/A
- Fundamental
- Price
- MOLN $5.04
- CIA $5.11
- Analyst Decision
- MOLN
- CIA
- Analyst Count
- MOLN 0
- CIA 0
- Target Price
- MOLN N/A
- CIA N/A
- AVG Volume (30 Days)
- MOLN 5.7K
- CIA 101.9K
- Earning Date
- MOLN 03-13-2025
- CIA 03-13-2025
- Dividend Yield
- MOLN N/A
- CIA N/A
- EPS Growth
- MOLN N/A
- CIA N/A
- EPS
- MOLN N/A
- CIA 0.43
- Revenue
- MOLN $7,105,397.00
- CIA $248,376,000.00
- Revenue This Year
- MOLN N/A
- CIA N/A
- Revenue Next Year
- MOLN $29.41
- CIA $3.85
- P/E Ratio
- MOLN N/A
- CIA $11.17
- Revenue Growth
- MOLN N/A
- CIA 3.02
- 52 Week Low
- MOLN $3.32
- CIA $1.78
- 52 Week High
- MOLN $12.70
- CIA $5.95
- Technical
- Relative Strength Index (RSI)
- MOLN 41.97
- CIA 60.35
- Support Level
- MOLN $5.22
- CIA $4.69
- Resistance Level
- MOLN $5.35
- CIA $4.95
- Average True Range (ATR)
- MOLN 0.12
- CIA 0.26
- MACD
- MOLN -0.03
- CIA 0.04
- Stochastic Oscillator
- MOLN 0.00
- CIA 67.86
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About CIA Citizens Inc. ($1.00 Par)
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. the Company derives its revenues principally from life insurance premiums earned for insurance coverages provided to insureds in our two operating segments and net investment income. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment.